peptide degradation is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | ACTH(4-7) analogue |
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Free N terminus, unmodified side chains |
| Molecular weight | 813.9 Da | Free base; salt forms differ |
| Appearance | White to off-white powder | Lyophilised solid |
| Solubility | Freely soluble in water | Hydrophilic; polar solvents preferred |
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
纯度评估以反相高效液相色谱为主，通过主峰面积百分比给出粗略结果，再配合电喷雾质谱核对分子量。氨基酸分析可验证组成比例，手性色谱或毛细管电泳用于检查残基构型。常见杂质包括缺失序列的短肽、氧化产物与二聚体。由于多数市售品不附带完整检验报告，独立第三方检测常被用来核实标称值。
从分子层面看，Semax 是线性七肽，没有二硫键、糖基或脂链修饰，N 端为游离氨基，C 端为游离羧基。分子含组氨酸与谷氨酸侧链，因此在水和甲醇等极性溶剂中溶解良好，在非极性溶剂中溶解有限。计算分子量约为 814 Da，与其质子化离子的质荷比吻合，可用于质谱确认。
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
=== Spectrum of collective cell migration === In the diagram immediately below, different morphologies of collective cell migration are characterized by their cohesiveness during migration (inversely related to density), as well as the number of nearest neighbours with which a cell interacts while moving (i.e. the topological arrangement of individual cells in the population). Cells (ellipses) can migrate in linear chains (top left), with persistent contact to cells either side of them, or along trails formed by preceding cells (bottom left). In migrating sheets, cells may maintain most of their nearest neighbours over time (top right), whereas in streaming migration cell–cell contacts occur at longer range and with potentially frequent neighbour rearrangement (bottom right). These concepts easily extend to three-dimensional migration, in which case the place of migrating sheets can be taken by moving clusters or spheroids.
==== Robust transport networks ==== According to FAO, robust transport networks can prevent or limit increases in travel time – and consequent impacts on food costs – when an adverse event limits or prevents access to critical network links. For example, flooding, whether from flash floods or from longer-term stagnant flooding, reduces the connectivity of any transport network, impacting the movement of people, goods and societal functioning in general. Damage from flooding can indirectly affect larger areas for a longer period of time, such as when there are traffic delays and congestion on alternative routes, increased journey distances/durations, increased fuel consumption and associated greenhouse gas (GHG) emissions. Due to climate change, transport networks are increasingly being exposed to extreme weather events. A study on the transport networks of 90 countries finds that where food is transported more locally and where the network is denser – such as in high-income countries and densely populated countries like China, India, Nigeria and Pakistan –, systematic disturbances have a much lower impact. Conversely, low-income countries have much lower levels of transport network resilience, although some exceptions exist. The study further simulates the effect of potential disruptions – namely floods – to food transport networks which illustrate that the loss of network connectivity that results when links become impassable potentially affects millions of people.
==== Translation ==== Two different sets of proteins are translated from viral mRNAs. The first set is represented by six structural proteins that include nucleocapsid protein (NP), phosphoprotein (P), matrix protein (M), fusion protein (F), neuraminidase (NA) and large protein (L). All these proteins have variable functions and are incorporated into the viral capsid (see the section "Virion structure" above). The second set is represented by seven non structural or accessory proteins. These proteins are translated from the polycistronic mRNA of P gene. This mRNA encodes eight translation products, and P-protein is only one of them. Alternative variants of translation are represented by V, W, C, C′, Y, Y′ and X proteins. The proteins C′, C, Y1, Y2 are products of mRNA alternative reading frame, they collectively referred as C-proteins or C-nested proteins and they share common C-terminal end. The X protein also shares the same C-terminal end and its translation also independently initiated by ribosomes. The proteins V and W are products of cotranscriptional mRNA editing. All these non-structural proteins have multiple functions, including the organization of viral RNA synthesis and helping the virus to infect host cells by escaping host innate immunity (see "Virus-induced immunosuppression" section above).
The process of acute inflammation is initiated by resident immune cells already present in the involved tissue, mainly resident macrophages, dendritic cells, histiocytes, Kupffer cells and mast cells. These cells possess surface receptors known as pattern recognition receptors (PRRs), which recognize (i.e., bind) two subclasses of molecules: pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). PAMPs are compounds that are associated with various pathogens, but which are distinguishable from host molecules. DAMPs are compounds that are associated with host-related injury and cell damage. At the onset of an infection, burn, or other injuries, these cells undergo activation (one of the PRRs recognize a PAMP or DAMP) and release inflammatory mediators responsible for the clinical signs of inflammation. Vasodilation and its resulting increased blood flow causes the redness (rubor) and increased heat (calor). Increased permeability of the blood vessels results in an exudation (leakage) of plasma proteins and fluid into the tissue (edema), which manifests itself as swelling (tumor). Some of the released mediators such as bradykinin increase the sensitivity to pain (hyperalgesia, dolor). The mediator molecules also alter the blood vessels to permit the migration of leukocytes, mainly neutrophils and macrophages, to flow out of the blood vessels (extravasation) and into the tissue. The neutrophils migrate along a chemotactic gradient created by the local cells to reach the site of injury.
Sources: en.wikipedia.org
Alkaptonuria Congenital disorders of joints Diabetes doubles the risk of having a joint replacement due to osteoarthritis, and people with diabetes have joint replacements at a younger age than those without diabetes. Ehlers–Danlos syndrome Injury to joints or ligaments (such as the ACL) Ligamentous deterioration or instability Marfan syndrome Obesity Joint infection
=== Climate change === Panera Bread includes a "Cool Food" pledge in its campaign to "curb global warming". Panera Bread provides American consumers with dietary guidelines to help them change their eating patterns to help reduce carbon emissions. Through the Cool Foods pledge, the company uses traffic lights for different healthy and unhealthy foods. Foods labeled "green" are branded healthy, while those labeled "yellow" are warned to be consumed in moderation. In 2015, Panera Bread also announced its policy against the use of genetically modified organisms (GMOs), making it the first food chain in the country to question the safety and environmental friendliness of these foods.
== Toxicity rates == In earlier years it was thought that apamin was a rather nontoxic compound (LD50 = 15 mg/kg in mice) compared to the other compounds in bee venom. The current lethal dose values of apamin measured in mice are given below. There are no data known specific for humans. Intraperitoneal (mouse) LD50: 3.8 mg/kg Subcutaneous (mouse) LD50: 2.9 mg/kg Intravenous (mouse) LD50: 4 mg/kg Intracerebral (mouse) LD50: 1800 ng/kg Parenteral (mouse) LD50: 600 mg/kg
=== Pharmaceuticals === Over 30 nitrile-containing pharmaceuticals are currently marketed for a diverse variety of medicinal indications with more than 20 additional nitrile-containing leads in clinical development. The types of pharmaceuticals containing nitriles are diverse, from vildagliptin, an antidiabetic drug, to anastrozole, which is the gold standard in treating breast cancer. In many instances the nitrile mimics functionality present in substrates for enzymes, whereas in other cases the nitrile increases water solubility or decreases susceptibility to oxidative metabolism in the liver. The nitrile functional group is found in several drugs.
YAN is a measurement of the primary organic (free amino acids) and inorganic (ammonia and ammonium) sources of nitrogen that can be assimilated by S. cerevisiae. There are several nitrogenous compounds found in must and wine including peptides, larger proteins, amides, biogenic amines, pyridines, purines and nucleic acids but these cannot be directly used by yeast for metabolism. Taken together, the total nitrogen content of grape must can range from 60 to 2400 mg of nitrogen per liter, however not all of this nitrogen will be assimilable. The lack of protease enzymes, which break down larger peptides into smaller components, that can work outside the cell, limits the size of the molecules that yeast can use as a source for nitrogen. The amount of YAN that winemakers will see in their grape musts depends on a number of components including grape variety, rootstock, vineyard soils and viticultural practices (such as the use of fertilizers and canopy management) as well as the climate conditions of particular vintages. Infections by mold, such as Botrytis cinerea (known as noble rot when it is desired) can reduce the amino acid content of grape must by as much as 61%. Some regions are noted for having low YAN such as Washington State which during a typical vintage will have 90% of tested must below 400 mg N/L and nearly a quarter be below 150 mg N/L. In the vineyard, nitrogen is taken up by the grapevine as nitrate (NO3−), ammonium or urea which gets reduced into ammonia.
Sources: en.wikipedia.org
Note that the incompressible case correspond to the assumption that the pressure constrains the flow so that the volume of fluid elements is constant: isochoric flow resulting in a solenoidal velocity field with
Due to the preference for a cis-amide bond with the preceding residue of C2-substituted pseudoprolines, their incorporation results in a kink conformation of the peptide backbone, thus preventing peptide aggregation, self-association, or β-structure formation.
None of these measures proved effective in significantly reducing opium use. In the following years, opioids, cocaine, and cannabis were associated with various ethnic minorities and targeted in other local jurisdictions. In 1908, Hamilton Wright was appointed United States Opium Commissioner. His wife, Elizabeth Washburn Wright, carried on much of his anti-opium campaign after his death in 1917. In 1906, the Pure Food and Drug Act, also known as the Wiley Act, addressed problems with tainted and adulterated food in the growing industrial food system, and with drug quality, by mandating ingredient labels and prohibiting false or misleading labeling. For drugs, a listing of active ingredients was required; a set of drugs deemed addictive or dangerous, that included opium, morphine, cocaine, caffeine, and cannabis, was specified. Oversight of the act was assigned to the US Department of Agriculture's Bureau of Chemistry, which evolved into the Food and Drug Administration in 1930.
liraglutide (Victoza for type 2 diabetes, Saxenda for weight management, manufactured by Novo Nordisk), approved in 2010/2014 dulaglutide (Trulicity, manufactured by Eli Lilly), approved in 2014 semaglutide (Ozempic and Rybelsus for diabetes, Wegovy for weight management, manufactured by Novo Nordisk), approved in 2021/2019/2021 tirzepatide (a GIP analog with dual GLP-1 receptor and GIP receptor agonism; Mounjaro for diabetes, Zepbound for weight management, manufactured by Eli Lilly), approved in 2022/2024 Discontinued:
In many European countries and elsewhere in the world, the most commonly found dihydrocodeine preparations are extended-release tablets made by encasing granules of the ingredient mixture, almost always using the bitartrate salt of dihydrocodeine, of four different sizes in a wax-based binder. The usual strengths are 60, 90, and 120 mg. Common trade names for the extended-release tablets are Didor Continus, Codidol, Codi-Contin, Dicodin (made in France and the major product containing the tartrate salt), Contugesic, DHC, and DHC Continus. Dihydrocodeine is available in Japan as tablets which contain 2.5 mg of dihydrocodeine phosphate and caffeine, the decongestant d,l-methylephedrine HCl, and the antihistamine chlorpheniramine, and packets of granules which effervesce like Alka-Seltzer with 10 mg of dihydrocodeine with lysozyme and chlorpheniramine, marketed for OTC sale as New Bron Solution-ACE. These two formulations may have once contained phenyltoloxamine citrate as the antihistamine component. Elsewhere in the Pacific Rim, Dicogesic in analogous to Glaxo/Smith-Kline's DF-118. The manufacturer of New Bron Solution-ACE; SS Pharmaceutical Co., Ltd, also markets an ibuprofen with dihydrocodeine product called S.Tac EVE, which also includes d,l-methylephedrine HCl, chlorpheniramine, anhydrous caffeine, and vitamins B1 and C. The Panlor series is manufactured by Pan-American Laboratories of Covington, Louisiana, and they also market several dihydrocodeine-based prescription cough syrups in the United States.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide built from the ACTH(4-7) sequence plus a Pro-Gly-Pro tail. It belongs to the family of short ACTH fragments studied for nervous-system effects. Its backbone contains only standard amino acids.
It contains the 4-7 fragment of adrenocorticotropic hormone extended at the C terminus. That truncation removes the region associated with steroidogenic activity. The design intent was to keep neurotrophic properties while avoiding full hormonal effects.
No natural source of the intact heptapeptide is known. It is produced by solid-phase peptide synthesis. Some related ACTH fragments arise as hormone processing products, but the Pro-Gly-Pro extension is a designed addition rather than a natural sequence.
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.